Pediatric Oncology | Specialty

Chemotherapy Sensitivity in Soft Tissue Sarcoma

July 29th 2016

Local Control in Metastatic Soft Tissue Sarcoma

July 29th 2016

Goals of Therapy in Sarcoma

July 29th 2016

Challenges in Treating Soft Tissue Sarcomas in Younger Populations

July 29th 2016

Soft Tissue Sarcoma: Factors Impacting Initial Approach

July 29th 2016

When to Suspect Sarcoma

July 29th 2016

FDA Panel Endorses Early Trials of Promising Anticancer Agents in Pediatric Patients

June 29th 2016

Members of the Pediatric Subcommittee of the FDA's Oncologic Drugs Advisory Committee voiced their support for new clinical trials examining promising cancer agents in pediatric patients.

FDA Approval Sought for Blinatumomab in Pediatric Acute Lymphoblastic Leukemia

March 3rd 2016

A supplemental biologics license application has been submitted to the FDA to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL

November 5th 2015

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).

Dr. Stephen Huang on Challenges in Pediatric Thyroid Cancer

October 22nd 2015

Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.

Survivors of Childhood Cancers Living Longer Due to Improvements in Care and Follow-up

May 31st 2015

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.

Intensified Chemotherapy Extends EFS for Children With Wilms Tumor

May 13th 2015

Treatment with an intensified chemotherapy regimen was associated with improvements in event-free survival for children with favorable histology Wilms tumor with loss of heterozygosity in chromosomes 1p and 16q.

CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL

April 24th 2015

The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Three FDA Approvals, NCI Director Resigns, and More

March 12th 2015

FDA Approves Dinutuximab for High-Risk Neuroblastoma

March 10th 2015

The FDA has approved dinutuximab in combination with interleukin-2, GM-CSF, and 13-cis-retinoic acid as a frontline therapy for pediatric patients with high-risk neuroblastoma.

Final Thoughts on AML and ALL

January 9th 2015

New Treatments in Acute Myeloid Leukemia

January 9th 2015

Role of Transplant in Acute Myeloid Leukemia

January 9th 2015

Therapeutic Targets in Acute Lymphoblastic Leukemia

January 9th 2015

CAR-Modified T Cell Therapy in ALL

January 9th 2015